Skip to content

Trial Summary

The purpose of this study is to assess the efficacy and safety of intratumoral (IT) MK-1454 in PLUS pembrolizumab (MK-3475) compared to pembrolizumab alone as a first line treatment of adults with metastatic or unresectable, recurrent head and neck squamous cell carcinoma (HNSCC).

Acronym:

MK-1454-002

ACTRN/NCT /ethics:

NCT04220866

Scientific title:

A Phase 2 Study in First Line Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma to Evaluate Intratumoral MK-1454 in Combination With IV Pembrolizumab vs IV Pembrolizumab Monotherapy

Sponsor / Cooperative group:

Merck Sharp & Dohme Corp.

Trial & Patient Characteristics

Cancer TypeHead and Neck
Trial TypeTreatment
PhasePhase II
Age Range18 years and older
SexBoth
Tumour Stream Head and neck squamous cell carcinoma
Cancer StageMetastatic or Widespread
Anticipated Start Date2020-03-04
Anticipated End Date2023-09-28

Participating Hospitals

HospitalCalvary Central Districts Hospital
Clinical Trial CoordinatorJulie Rowe
Emailjulie.rowe@calvarycare.org.au
Phone08 8239 9536
Principal InvestigatorDr Rohit Joshi
Recruitment StatusRecruiting